杭州民生健康药业股份 有限公司 章 程 二〇二五年四月 1 | | | | 第一章 | 总 | 则 3 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 4 | | 第三章 | 股 | 份 4 | | 第一节 | | 股份发行 4 | | 第二节 | | 股份增减和回购 5 | | 第三节 | | 股份转让 6 | | 第四章 | | 股东和股东会 7 | | 第一节 | | 股东的一般规定 7 | | 第二节 | | 控股股东和实际控制人 10 | | 第三节 | | 股东会的一般规定 11 | | 第四节 | | 股东会的召集 13 | | 第五节 | | 股东会的提案与通知 14 | | 第六节 | | 股东会的召开 16 | | 第七节 | | 股东会的表决和决议 18 | | 第五章 | | 董事和董事会 22 | | 第一节 | | 董 事 22 | | 第二节 | | 董事会 25 | | 第三节 | | 独立董事 28 | | 第四节 | | 董事会专门委员会 31 | | 第六章 | | 高级管理人员 32 | | 第七章 | | 财务会计制度、利润分配和审计 ...

Financial Performance - The company's operating revenue for 2024 reached ¥641,252,292.20, representing a 10.23% increase compared to ¥581,733,150.83 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥91,834,052.10, up 7.24% from ¥85,633,797.95 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥87,209,271.59, reflecting a 10.13% increase from ¥79,186,962.41 in 2023[18]. - The net cash flow from operating activities was ¥108,458,465.37, a slight increase of 0.28% compared to ¥108,152,661.81 in 2023[18]. - The total assets at the end of 2024 amounted to ¥1,744,608,477.33, marking a 5.87% increase from ¥1,647,809,834.45 at the end of 2023[18]. - The net assets attributable to shareholders increased by 3.92% to ¥1,530,846,241.06 at the end of 2024, compared to ¥1,473,060,211.58 at the end of 2023[18]. - Basic earnings per share for 2024 were ¥0.26, down 10.34% from ¥0.29 in 2023[18]. - The weighted average return on net assets decreased to 6.12% in 2024 from 9.50% in 2023, a decline of 3.38%[18]. Market and Industry Insights - The company operates in the dietary supplement sector, focusing on vitamins and minerals, which is experiencing stable growth due to increasing health awareness among consumers[28]. - The market for dietary supplements in China is expected to grow, driven by rising health consciousness and an aging population, with the elderly population projected to reach 220 million by the end of 2024[32]. - The dietary supplement market in China is still significantly underdeveloped compared to developed countries, indicating substantial growth potential[30]. - Recent government policies, such as the "Healthy China 2030" initiative, are expected to provide long-term support for the health supplement industry[29]. Product Development and Innovation - The company is enhancing its product matrix by expanding into treatment-oriented OTC medications and probiotics, while also strengthening brand development and sales channels[34]. - The company is committed to continuous R&D innovation to enhance its product offerings and maintain competitiveness in the health supplement market[34]. - The company has introduced 1 new drug approval and 7 new patents during the reporting period, enhancing its core technology system[49]. - The newly approved drug, Aluminum Magnesium Hydroxide Suspension, is indicated for chronic gastritis and related gastric discomfort symptoms[49]. - The company is in the stability research phase for a vitamin D complex formulation aimed at preventing rickets and osteoporosis, with the goal of completing product development and obtaining approval[72]. - A new broad-spectrum multi-vitamin supplement is under development, with partial completion of product development and approval expected to enhance the company's R&D pipeline[72]. - The company has completed the selection and identification of its own strains for probiotic products, reaching an industrialization level[75]. Sales and Distribution - The company has expanded its online sales channels on platforms like Tmall, JD.com, and Pinduoduo, enhancing product accessibility for consumers[40]. - The main sales model is a buyout distribution system, focusing on large national and regional pharmaceutical distributors, with a dedicated business team in key provinces[39]. - The company's sales model is primarily based on distribution, with 87.81% of total revenue in 2024 derived from this channel, highlighting potential risks associated with distributor management[116]. Financial Management and Investments - The company raised a total of RMB 89,138.60 million through the issuance of 89,138,600 shares at RMB 10.00 per share, with net proceeds of RMB 79,329.73 million after deducting issuance costs of RMB 9,808.87 million[96]. - The company has committed to achieving audited net profits of no less than RMB 6 million, RMB 8 million, and RMB 10 million for the years 2025, 2026, and 2027 respectively, totaling a minimum of RMB 24 million over three years[89]. - The company is focusing on cash management of idle raised funds to optimize financial performance[97]. - The company plans to use up to RMB 6.5 billion of idle funds for cash management, ensuring it does not affect the construction of fundraising projects[100]. Governance and Compliance - The company maintains complete independence in assets, personnel, finance, institutions, and business from its controlling shareholders and actual controllers[139]. - The company has established a comprehensive governance structure, including a board of directors, supervisory board, and general meeting of shareholders, ensuring compliance with relevant laws and regulations[143]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[130]. - The company has established a robust performance evaluation and incentive mechanism for senior management, aligning interests among shareholders, the company, and core employees[135]. Employee and Talent Management - The total number of employees at the end of the reporting period is 514, with 453 in the parent company and 61 in major subsidiaries[184]. - The company has implemented a performance-based compensation system aimed at aligning employee performance with organizational goals[188]. - The company is focusing on talent development and has established a multi-channel career development system for employees[189]. Future Outlook and Strategy - The company plans to implement a "Four New" strategy focusing on new products, new businesses, new models, and new projects to drive sustainable growth[106]. - Future R&D investments will focus on gut health, sleep health, metabolism, and chronic diseases, targeting specific demographics such as the elderly, women, and children[111]. - The company is committed to ensuring that the use of funds does not alter the intended purpose of the fundraising[100].

Financial Performance - The company's revenue for Q1 2025 reached ¥271,466,917.97, representing a 15.70% increase compared to ¥234,624,438.88 in the same period last year[5] - Net profit attributable to shareholders was ¥62,705,133.38, up 6.51% from ¥58,872,271.43 year-on-year[5] - Basic earnings per share increased to ¥0.1759, reflecting a growth of 6.54% from ¥0.1651 in the previous year[5] - Total operating revenue for the current period reached ¥271,466,917.97, an increase of 15.65% compared to ¥234,624,438.88 in the previous period[25] - Net profit for the current period was ¥62,705,720.26, representing a growth of 6.93% from ¥58,872,271.43 in the previous period[26] - Earnings per share (EPS) for the current period was ¥0.1759, compared to ¥0.1651 in the previous period, reflecting a 4.84% increase[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,977,059,453.66, a 13.32% increase from ¥1,744,608,477.33 at the end of the previous year[5] - The company's total current liabilities amounted to CNY 237,134,000.00, with accounts payable decreasing from CNY 21,229,670.85 to CNY 12,778,204.76[22] - Non-current assets totaled CNY 530,136,336.59, up from CNY 487,047,473.78, indicating an increase of about 8.8%[22] - Total liabilities reached ¥262,335,323.34, compared to ¥213,762,236.27 in the previous period, marking an increase of 22.69%[24] - Non-current liabilities increased to ¥15,359,763.06, up from ¥7,095,842.24 in the previous period, indicating a significant rise of 116.06%[24] Cash Flow - The net cash flow from operating activities decreased by 11.40% to ¥118,827,835.83 from ¥134,109,804.54 in the same period last year[5] - Cash inflow from operating activities totaled ¥309,974,936.40, slightly up from ¥301,545,548.82 in the previous period[29] - The net cash flow from operating activities was $118,827,835.83, a decrease from $134,109,804.54 in the previous period, reflecting a decline of approximately 11.5%[30] - Cash outflows from operating activities totaled $191,147,100.57, compared to $167,435,744.28 previously, indicating an increase of about 14.2%[30] - The net cash flow from investing activities was -$186,770,263.94, worsening from -$49,693,920.20, representing a decline of approximately 276.5%[30] - Cash inflows from investing activities surged to $622,736,623.57, up from $56,440,603.15, marking an increase of about 1003.1%[30] - Total cash and cash equivalents at the end of the period were $271,944,555.93, down from $512,227,863.05, reflecting a decrease of approximately 47.1%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,603, with the largest shareholder holding 66.75% of the shares[15] - Total equity attributable to shareholders of the parent company was ¥1,609,971,284.17, up from ¥1,530,846,241.06, reflecting a growth of 5.14%[24] Investment and Financial Assets - The company's trading financial assets increased by 39.6% to ¥692,594,336.60 due to an increase in wealth management and structured deposits[11] - The company reported a significant increase in investment income, which rose by 285.6% to ¥1,698,923.57 compared to ¥440,603.15 in the previous year[13] - The company reported a financial income of ¥1,698,923.57, significantly higher than ¥440,603.15 in the previous period, indicating a growth of 285.66%[26] - The company reported a significant increase in derivative financial assets, rising to CNY 692,594,336.60 from CNY 496,195,455.42, a growth of approximately 39.5%[21] Operational Efficiency - Inventory decreased by 36.3% to ¥67,258,665.94, attributed to improved inventory management[11] - Trade receivables increased to CNY 61,161,165.83 from CNY 46,985,494.89, representing a growth of about 30.2%[21] - Total operating costs amounted to ¥200,726,477.27, up 17.63% from ¥170,660,081.11 in the prior period[25] Regulatory and Future Outlook - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[32] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[31] - The company has not disclosed any new product developments or market expansion strategies in the current report[19] - There is no mention of mergers or acquisitions in the latest financial report[19]

证券代码：301507 证券简称：民生健康 公告编号：2025-009 杭州民生健康药业股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 2025 年 4 月 11 日，杭州民生健康药业股份有限公司（以下简称"公司"）通 过回购专用证券账户，以集中竞价交易方式首次回购公司股份 75,100 股，占目 前公司总股本的比例为 0.02%，最高成交价为 12.08 元/股，最低成交价为 12.04 元/股，支付金额为 905,687.00 元（不含交易费用）。 一、 回购股份的基本情况 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公 告》（公告编号：2025-004）、《回购报告书》（公告编号：2025-007）。 二、 首次回购公司股份的具体情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-008 杭州民生健康药业股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 130 万-145 万股，预计回购资金总额不超过人民币 次回购方案之日起 12 个月内。 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公 告》（公告编号：2025-004）、《回购报告书》（公告编号：2025-007）。 二、 公司实施回购方案的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 披露截至上月末的回购进展情况。现将公司回购股份的进展 ...

杭州民生健康药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 证券代码：301507 证券简称：民生健康 公告编号：2025-008 回购方案的实施情况：截至 2025 年 3 月 31 日，杭州民生健康药业股份 有限公司（以下简称"公司"）通过集中竞价交易方式已累计回购股份 0 股，占 公司当前总股本的 0%。公司暂未回购股份。 一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 130 万-145 万股，预计回购资金总额不超过人民币 2,871.00 万元，具体以实际回购情况为准；回购实施期限为自董事会审议通过本 次回购方案之日起 12 个月内。 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 ...

（一）回购方案的主要内容 1.回购股份的种类：公司已发行的无限售条件的人民币普通股（A股）股票。 证券代码：301507 证券简称：民生健康 公告编号：2025-007 杭州民生健康药业股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 杭州民生健康药业股份有限公司（以下简称"公司"）于2025年3月19日召 开第二届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股 份的议案》，公司拟通过集中竞价交易方式以自有资金回购部分社会公众股份， 用于股权激励。根据《公司章程》的相关规定，本次回购方案在董事会的审议权 限范围内，经三分之二以上董事出席的董事会会议决议通过即可，无需提交股东 大会审议。 （二）相关股东、董事、监事、高级管理人员是否存在减持计划 2.回购股份的用途：拟用于股权激励。若公司未能在股份回购实施结果暨股 份变动公告日后3年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。 如国家对相关政策作调整，则本回购方案按调整后的政策实行。 3.回购方式：集中竞价交易方式。 4.回购股份的价格区间： ...

证券代码：301507 证券简称：民生健康 公告编号：2025-006 杭州民生健康药业股份有限公司 关于回购股份事项前十名股东和前十名无限售条 件股东持股情况的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日 召开了第二届董事会第七次会议，会议审议通过了《关于以集中竞价交易方式回 购公司股份的议案》。具体内容详见公司于 2025 年 3 月 21 日在巨潮资讯网 一、董事会公告回购股份决议的前一个交易日（即 2025 年 3 月 20 日）登记 在册的前十名股东持股情况 | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 （%） | | --- | --- | --- | --- | | 1 | 杭州民生药业股份有限公司 | 238,000,000 | 66.75 | | 2 | 浙江普华天勤股权投资管理有限公司 －兰溪普华凌聚创业投资合伙企业 | 4,821,303 | 1.35 | | | （有限合伙） | | | | 3 | 杭州景牛企业管理合伙企业 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-005 关于公司取得米诺地尔搽剂药品注册证书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，杭州民生健康药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的米诺地尔搽剂（规格 1：2%（60 毫升：1.2 克），规格 2： 5%（60 毫升：3.0 克））《药品注册证书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：米诺地尔搽剂 英文名/拉丁名：Minoxidil Liniment 证书编号：2025S00766、2025S00767 主要成份：米诺地尔 杭州民生健康药业股份有限公司 药品批准文号：国药准字 H20253660、国药准字 H20253661 药品批准文号有效期：至 2030 年 03 月 17 日 上市许可持有人：名称：杭州民生健康药业股份有限公司 地址：浙江省杭州市临平区东湖街道新天路 101 号 二、药品相关情况 剂型：搽剂 规格：2%（60 毫升：1.2 克）、5%（60 毫升：3.0 克） 注册分类：化学药品 3 类 药品注册 ...

杭州民生健康药业股份有限公司（以下简称"公司"）于2025年3月13日收到 公司实际控制人、董事长竺福江先生出具的《关于提议杭州民生健康药业股份有 限公司以集中竞价交易方式回购公司股份的函》。竺福江先生提议公司通过集中 竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，用于股权激励。 提议函具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司实际控制人、董事长竺福江先生 证券代码：301507 证券简称：民生健康 公告编号：2025-002 杭州民生健康药业股份有限公司 关于公司实际控制人、董事长提议回购公司股 份的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 目前公司主营业务与财务状况良好。基于对公司未来持续稳定发展的信心和 长期投资价值的认可，为切实维护公司全体投资者利益，增强投资者信心，同时 为了不断完善公司长效激励机制，充分调动公司员工的积极性，有效地将股东利 益和公司利益紧密结合在一起，推进公司长远、稳定、持续的发展，在综合考虑 公司财务状况、经营状况以及未来盈利能力的情况下，竺福江先生提议公司通过 集中竞价交易方式 ...